TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.
TME Pharma has raised $2.6M across 1 round. Its most recent round was a Series Unknown of $2.6M in Oct 2024. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
TME Pharma is featured in
Similar companies
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of sustainable and food alternatives.
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and pathogens in food.
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is dedicated to researching Tumor-Associated Carbohydrate Antigens (TACAs) as a potential new target for cancer therapy. TACAs are expressed specifically in tumors due to abnormal glycosylation, and contribute to processes like metastasis, angiogenesis, and immune suppression. Tacalyx utilizes advanced carbohydrate synthesis technology to create pure TACA structures, which are then used to develop antibodies for innovative cancer treatments.
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and scalable production.
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their solubility, stability, and absorption. Our OPTISOLV® Technology helps deliver natural actives into food, nutraceuticals, pharmaceuticals, and personal care products — more effectively and efficiently. Our goal is to support brands in creating their next product innovation. Developed in Germany. Produced in Europe.
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored expression systems for enzymes from picoliter to large-scale fermentation. They are building on their experience in engineering a wide range of industrial organisms including bacteria, yeast, and filamentous fungi. Their customized enzyme solutions are applicable across industries such as circular economy, food, and feed. Picea Biosolutions is headquartered in Offenburg, Baden-Wurttemberg and was founded in 2022.
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.
iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.